Article Figures & Data
Files in this Data Supplement:
- Supplementary Figure Legends, Figures S1 - S7, Tables S1 - S8 - Supplementary Figure S1. CREBBP binds to GC-specific super-enhancers. Supplementary Figure S2. Crebbp and EP300 expression in the B cell subsets development in Crebbpfl/flCÎ³1-Cre and Crebbpfl/flCD19-Cre mice. Supplementary Figure S3. GSEA analysis of Crebbpfl/fl vs Crebbp+/+ CÎ³1-Cre GC B cells. Supplementary Figure S4. Analysis of GC B cell responses in the CÎ³1-Cre and CD19-Cre cohorts. Supplementary Figure S5. Analysis of plasma cell differentiation in the CÎ³1-Cre and CD19-Cre cohorts. Supplementary Figure S6. Distribution pattern of CREBBP mutations in FL and de novo DLBCL. Supplementary Figure S7. Analysis of Crebbp-conditional knockout cohorts. Supplementary Table S1. Overlap between CREBBP bound regions and predicted superenhancers in GC B cells. Supplementary Table S2. Genes differentially expressed in Crebbpfl/fl vs Crebbp+/+ GC B cells. Supplementary Table S3. List of CREBBP "core target" genes (bound by CREBBP in human GC B cells and downregulated in Crebbpfl/flCÎ³1-Cre GC B cells). Supplementary Table S4. Pathway enrichment analysis of CREBBP "core target" genes (bound by CREBBP in human GC B cells and downregulated in CÎ³1-Cre Crebbpfl/fl GC B cells). Supplementary Table S5. Leading edge associated with GSEA of CREBBP core target genes in the rank of genes differentially expressed in DZ vs LZ GC B cells. Supplementary Table S6. Pathway enrichment analysis of genes co-bound by CREBBP and BCL6 in human GC B cells. Supplementary Table S7. V gene rearrangement analysis of B-cell lymphomas in the Crebbpfl/f/CÎ³1-Cre /VavP-Bcl2 conditional knock-out mouse model. Supplementary Table S8. List of antibodies used in FACS analysis.